$60 million to be spent on DTC ads for Sepracor sleep drug

Share this article:
Sepracor will spend an estimated $60 million to advertise its new insomnia drug Lunesta directly to consumers, according to a Wall Street Journal report. The drug was approved by the FDA Wednesday.
Handling the DTC account for Lunesta is McCann-Erickson, with professional work done by Torre Lazur McCann Healthcare.
Lunesta was formerly known as Estorra. Its name was changed to avoid confusion with another drug on the market, a company official said. 
Lunesta will enter the $2 billion market for sleep aids, which is led by Sanofi-Aventis' Ambien. Ambien spent $65 million on U.S. media in 2002, according to Nielsen-Monitor Plus.
Analysts estimate Lunesta could start out with annual sales of $400 million, rising to $750 million or more.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.